Click here to access this information as an RSS feed. Or use the following link in your feed-reading program:
EACR-23 - from Basic Research to Personalised Cancer Treatment
17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress
Reinforcing multidisciplinarity, Amsterdam, 27 September - 1 October 2013
The 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress is an ideal platform for consolidating expertise and resources across borders and speeding up the translation of discoveries into applications that impact healthcare delivery. Organised in partnership with EACR, ESSO 33, EONS and SIOPE, focus has been placed on enhancing the scientific excellence of the ECC 2013 programme to ensure it plays a pivotal role in facilitating these processes.
A record 38% increase has occurred in the number of abstracts submitted in comparison to the Stockholm Congress in 2011. The largest number of submissions came from Japan, followed by The Netherlands, UK, Italy, Spain and the USA. With such record submissions, the Congress will play a pivotal role in establishing standards for the future in Europe.
Basic, translational research and drug development make up 23 percent of all submissions, clearly demonstrating the importance of basic and translational research to this meeting. This highlights the uniqueness of the Congress in bringing together scientists and clinicians to discuss the fundamentals of cancer, furthering the understanding and development of its diagnosis, treatment and care. There were also increased numbers of radiotherapy, systemic therapy, surgery, pathology and radiology abstracts, demonstrating the true multidisciplinarity of the meeting.
Abstract submissions will reopen again for late-breaking abstracts from 24 July until 7 August, where we hope to attract the latest practice-changing data to the European Cancer Congress 2013.